A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer

Official title

A Phase II Study to Evaluate the Safety and Efficacy of SYS6010 Combined With Osimertinib Versus Osimertinib as Neoadjuvant Therapy in Participants With Resectable Stage II-IIIB Non-squamous Non-small Cell Lung Cancer With EGFR Mutation Positive

Overview

To evaluate the safety and efficacy of SYS6010 combined with osimertinib as neoadjuvant therapy for patients with resectable EGFR mutation non-squamous non-small cell lung cancer.

Detailed description

This study includes three stages: a neoadjuvant therapy stage, a surgery stage, and an adjuvant follow-up stage. In the neoadjuvant therapy stage, eligible participants will be stratified by stage (Stage II and Stage III) and mutation type (19Del and L858R) and randomized in a 1:1 ratio to the SYS6010 combined with osimertinib treatment group and the osimertinib monotherapy group. Neoadjuvant therapy will be administered for 3 cycles.

In the surgery stage, the feasibility of surgery will be assessed by a thoracic surgery investigator. Surgery should be performed between Week 10 and Week 12 (i.e., D64-D84 after the first dose of neoadjuvant therapy). Tumor samples collected during surgery will be sent to a central pathology laboratory to assess pathological response.

In the adjuvant therapy stage, all participants who undergo surgery will subsequently enter the adjuvant therapy stage. Participants who do not undergo surgery for reasons other than disease progression will also enter the adjuvant therapy stage.

Interventions

• Drug SYS6010
  SYS6010 by intravenous (IV) infusion
• Drug Osimertinib
  Osimertinib, oral
• Drug Pemetrexed
  500 mg/m\^2 by IV infusion, Q3W
• Drug Cisplatin
  75 mg/m\^2 by IV infusion, Q3W
• Drug Carboplatin
  AUC 5 mg/mL•min by IV infusion, Q3W

Primary outcome measures

• Major Pathological Response (MPR) Rate [Time frame: Within 8 weeks post-surgery]
• Pathological Complete Response (pCR) Rate [Time frame: Within 8 weeks post-surgery]
• Downstaging from N2 to N0/N1 or N1 to N0 at the time of surgery [Time frame: Within 8 weeks post-surgery]
• Disease-Free Survival (DFS) [Time frame: Up to approximately 5.5 years after the last participant enrolled]
• Event-Free Survival (EFS) [Time frame: Up to approximately 5.5 years after the last participant enrolled]
• Objective Response Rate (ORR) [Time frame: Up to approximately 5.5 years after the last participant enrolled]
• Overall Survival (OS) [Time frame: Up to approximately 5.5 years after the last participant enrolled]
• Incidence of Adverse Events (AEs) [Time frame: Up to approximately 5.5 years after the last participant enrolled]
• Anti-drug Antibodies (ADAs) to SYS6010 [Time frame: Up to approximately 5.5 years after the last participant enrolled]

Eligibility criteria

Inclusion criteria

• Able to understand and voluntarily sign the written informed consent form (ICF);
• Age 18-75 years, regardless of sex;
• Histologically or cytologically confirmed non-squamous non-small cell lung cancer, staged as resectable or potentially resectable Stage II-IIIB disease according to the International Association for the Study of Lung Cancer (IASLC) 8th Edition TNM staging criteria;
• Must be eligible for complete surgical resection of the primary tumor;
• Nodal status must be evaluated by whole-body FDG-PET and contrast-enhanced CT;
• Confirmed presence of an EGFR-sensitizing mutation (exon 19 deletion or exon 21 L858R mutation, co-mutation with other EGFR sites is allowed), as tested by a central laboratory or local testing facility;
• No prior systemic anti-tumor therapy (including chemotherapy, biotherapy, targeted therapy, immunotherapy);
• At least one measurable lesion at baseline as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1;
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1;
• Life expectancy ≥6 months;
• Adequate major organ and bone marrow function;
• Women or men of childbearing potential must use highly effective contraception.

1\. Able to understand and voluntarily sign the written informed consent form (ICF); 2. Age 18-75 years, regardless of sex; 3. Histologically or cytologically confirmed non-squamous non-small cell lung cancer, staged as resectable or potentially resectable Stage II-IIIB disease according to the International Association for the Study of Lung Cancer (IASLC) 8th Edition TNM staging criteria; 4. Must be eligible for complete surgical resection of the primary tumor; 5. Nodal status must be evaluated by whole-body FDG-PET and contrast-enhanced CT; 6. Confirmed presence of an EGFR-sensitizing mutation (exon 19 deletion or exon 21 L858R mutation, co-mutation with other EGFR sites is allowed), as tested by a central laboratory or local testing facility; 7. No prior systemic anti-tumor therapy (including chemotherapy, biotherapy, targeted therapy, immunotherapy); 8. At least one measurable lesion at baseline as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1; 9. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1; 10. Life expectancy ≥6 months; 11. Adequate major organ and bone marrow function; 12. Women or men of childbearing potential must use highly effective contraception.

Exclusion criteria

• Diagnosis of Stage I, Stage IIIB with N3, and Stage IIIC, IVA, and IVB non-small cell lung cancer;
• Multiple primary malignancies (refer to exclusion criterion #8 for synchronous primary lung cancer) OR a mixed histology of SCLC and NSCLC;
• T4 stage lung cancer due to invasion of the great vessels, carina, trachea, esophagus, heart, or vertebral body; and/or bulky N2 disease;
• Eligible only for segmentectomy or wedge resection;
• Receipt of Chinese patent medicine preparations indicated for the treatment of lung cancer within 1 week before randomization;
• Major surgery or severe traumatic injury within 4 weeks before the first study treatment, or expected to undergo major surgery during the study period;
• History of other primary malignant tumor (including any known or suspected concurrent primary lung cancer);
• History of autoimmune disease, immunodeficiency, or organ transplant (except for corneal transplant);
• Refractory nausea, vomiting, chronic gastrointestinal disease, inability to swallow drugs orally;
• Evidence of severe or uncontrolled medical conditions (including uncontrolled hypertension, diabetes mellitus, etc,);
• Active or prior history of interstitial lung disease (ILD)/pneumonitis;
• Expected to receive live vaccine therapy within 30 days after randomization;
• History of a definite neurological or mental disorder; known allergy, hypersensitivity, or intolerance to the study drugs or any of their excipients;
• Pregnant or lactating women;

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Open label

Primary purpose

Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07256509 · SYS6010-013

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗